Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Erosive arthritis.

Georg Schett1

  • 1Department of Internal Medicine 3, University of Erlangen-Nurnberg, Erlangen, Germany. georg.schett@med3.imed.uni-erlangen.de

Arthritis Research & Therapy
|July 20, 2007
PubMed
Summary
This summary is machine-generated.

Chronic inflammatory arthritis causes bone loss and disability. Targeting osteoclast formation with denosumab, which blocks receptor activator of nuclear factor-kappaB ligand (RANKL), may prevent this structural damage.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A model of chronic enthesitis and new bone formation characterized by multimodal imaging.

Disease models & mechanisms·2018
Same author

A comparative analysis of articular bone in large cohort of patients with chronic inflammatory diseases of the joints, the gut and the skin.

Bone·2018
Same author

Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.

Seminars in arthritis and rheumatism·2018
Same author

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.

RMD open·2018
Same author

Physiological effects of modulating the interleukin-6 axis.

Rheumatology (Oxford, England)·2018
Same author

Group 2 Innate Lymphoid Cells Attenuate Inflammatory Arthritis and Protect from Bone Destruction in Mice.

Cell reports·2018
Same journal

Alterations in systemic and skeletal muscle myostatin regulation are most prominent at disease onset and associate with muscle-related outcomes in idiopathic inflammatory myopathies.

Arthritis research & therapy·2026
Same journal

Plasma proteome differences between giant cell arteritis and polymyalgia rheumatica: a pilot study.

Arthritis research & therapy·2026
Same journal

Elucidating the mechanism of taurine in alleviating osteoarthritis progression based on bioinformatics, machine learning algorithm, and experimental validation.

Arthritis research & therapy·2026
Same journal

Discovery of biomarkers for primary Sj ögren's syndrome based on multi-omics data, construction of diagnostic models, and clinical correlation analysis.

Arthritis research & therapy·2026
Same journal

Identification of distinct subgroups in Chinese patients with Behçet's syndrome via cluster analysis of immune cells and clinical features.

Arthritis research & therapy·2026
Same journal

Artemisinin increases susceptibility to ferroptosis of fibroblast-like synoviocytes in rheumatoid arthritis.

Arthritis research & therapy·2026
See all related articles

Area of Science:

  • Rheumatology
  • Immunology
  • Bone Biology

Background:

  • Chronic inflammatory arthritis, including rheumatoid arthritis, is characterized by linked processes of inflammation and bone degradation.
  • This bone loss and erosion of articular bone contribute significantly to patient disability.
  • Osteoclasts play a critical role in the resorption of bone and mineralized cartilage within inflamed joints.

Purpose of the Study:

  • To investigate the role of osteoclast differentiation factors in inflammatory bone loss.
  • To evaluate the potential of blocking osteoclast formation as a strategy to prevent structural damage in arthritis.
  • To assess denosumab, a receptor activator of nuclear factor-kappaB ligand (RANKL) neutralizing antibody, as a therapeutic agent.

Main Methods:

  • The study focuses on the biological mechanisms linking inflammation and bone degradation in arthritis.

Related Experiment Videos

  • It examines the up-regulation of osteoclast differentiation factors, specifically receptor activator of nuclear factor-kappaB ligand (RANKL), in synovial membranes.
  • The therapeutic potential of denosumab, an antibody targeting RANKL, is discussed.

    • Main Results:

    • Chronic inflammatory arthritis leads to significant inflammatory bone loss and articular bone erosion.
    • Osteoclasts are crucial for bone resorption in this context.
    • Elevated levels of RANKL in inflamed joints promote abundant osteoclast activity and rapid tissue degradation.

    Conclusions:

    • Osteoclast blockade is a key strategy for preventing structural damage in inflammatory arthritis.
    • Denosumab, by neutralizing RANKL, presents a promising therapeutic approach to inhibit inflammatory bone loss and mitigate disability in rheumatoid arthritis.